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Purpose. We evaluated the impact a prior cancer diagnosis had on the risk of prostate-cancer-specific mortality (PCSM) and all-
cause mortality (ACM) in men with PC. Methods. Using the SEER data registry, 166,104 men (median age: 66) diagnosed with
PC between 2004 and 2007 comprised the study cohort. Competing risks and Cox regression were used to evaluate whether a
prior cancer diagnosis impacted the risk of PCSM and ACM adjusting for known prognostic factors PSA level, age at and year of
diagnosis, race, and whether PC treatment was curative, noncurative, or active surveillance (AS)/watchful waiting (WW). Results.
At a median followup of 2.75 years, 12,453 men died: 3,809 (30.6%) from PC. Men with a prior cancer were followed longer, had
GS 8 to 10 PC more often, and underwent WW/AS more frequently (𝑃 < 0.001). Despite these differences that should increase the
risk of PCSM, the adjusted risk of PCSM was significantly decreased (AHR: 0.66 (95% CI: (0.45, 0.97); 𝑃 = 0.033), while the risk
of ACM was increased (AHR: 2.92 (95% CI: 2.64, 3.23); 𝑃 < 0.001) in men with a prior cancer suggesting that competing risks
accountedforthereductionintheriskofPCSM.Conclusion.Anassessmentoftheimpactthatapriorcancerhasonlifeexpectancy
is needed at the time of PC diagnosis to determine whether curative treatment for unfavorable-risk PC versus AS is appropriate.
1. Introduction
Whilefavorable-risk(PSA≤20;T2bcategoryorless;Gleason
score ≤ 7[ 1]) prostate cancer (PC) can have a long natural
history [2] and is often curable, unfavorable-risk PC (which
comprises approximately 20% of cases) accounts for the
majority of prostate cancer deaths [3]. Men of PC bearing
age are also at risk for a metachronous cancer (i.e., history
of or subsequent diagnosis of another cancer). When consid-
ering life expectancy in men with PC, competing risks are
particularly relevant in men with favorable-risk disease [4–
10],inordertoavoidovertreatmentofPCwherethepotential
toxicities of treatment can be sustained with no prolongation
in survival.
To our knowledge, no study has investigated the impact
that the comorbidity of a prior cancer has on the risk of
PCSM.
Therefore, we used a SEER population database registry
to evaluate the impact that a prior cancer had on the risk
of PCSM and all-cause mortality (ACM) in men with newly
diagnosed, node negative, nonmetastatic PC, adjusting for
ageatandyearofdiagnosis,race,initialtreatment(curativeor
noncurative) or active surveillance (AS) or watchful waiting
(WW), and known PC prognostic factors.
2. Methods
2.1. Patients Selection and SEER Data Registry. We used a
population-based registry, SEER [11], in order to identify
166,104 men diagnosed with prostate cancer between 2004
and 2007. The inclusion period was limited to 2004–2007
when PSA data was available. The registries report infor-
mation on age, date of diagnosis, demographics, tumor
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Table1:Comparisonofthedistributionofclinicalcharacteristicsofthe166,104menstratifiedbyahistoryofcancerpriortothePCdiagnosis
versus no prior cancer.
Clinical characteristics Number (%) of men without a prior cancer Number (%) of men with a prior cancer 𝑃 value
𝑁=164,647 𝑁=1,457
Race
African American 20208 (12.3%) 108 (7.4%) <0.001
Other 144439 (87.7%) 1349 (92.6%)
Year of diagnosis (range)
2004 39609 (24.1%) 392 (26.9%)
0.035 2005 37072 (22.5%) 335 (23.0%)
2006 42810 (26.0%) 366 (25.1%)
2007 45156 (27.4%) 364 (25.0%)
Age at diagnosis
Median (IQR) (yr) 66 (60, 73) 72 (66, 78) 0.001
<50yr 5206 (3.2%) 9 (0.6%)
<0.001 50–59yr 35570 (21.6%) 115 (7.9%)
60–69yr 62463 (37.9%) 437 (30.0%)
≥70yr 61408 (37.3%) 896 (61.5%)
Gleason score
≤6 77736 (47.2%) 649 (44.5%)
<0.001 7 62016 (37.7%) 529 (36.3%)
8 to 10 24895 (15.1%) 279 (19.2%)
Clinical tumor stage
1c 61793 (37.5%) 612 (42.0%)
<0.001 2a–2c 87327 (53.0%) 737 (50.6%)
3-4 15527 (9.4%) 108 (7.4%)
PSA
Median (IQR) 6.5 (4.7, 10.6) 7.0 (4.7, 12.3) 0.59
≤4.0ng/mL 23839 (14.5%) 230 (15.8%)
<0.001 >4.0–10.0ng/mL 96632 (58.7%) 746 (51.2%)
10.1–20.0ng/mL 25360 (15.4%) 297 (20.4%)
>20.0ng/mL 18816 (11.4%) 184 (12.6%)
Risk group
Low risk 28682 (17.4%) 240 (16.5%)
0.01 Intermediate risk 91819 (55.8%) 778 (53.4%)
High risk 44146 (26.8%) 439 (30.1%)
Treatment approach
Curative 123674 (75.1%) 954 (65.5%)
<0.001 Other Rx 4017 (2.4%) 59 (4.1%)
Watchful-waiting/active surveillance 36956 (22.5%) 444 (30.5%)
Median followup (IQR) (years) 2.75 (1.85, 3.92) 3.0 (2.0, 4.17) <0.001
CI: confidence interval. Dx: diagnosis. IQR: interquartile range. PC: prostate cancer. Yr: year.
characteristics, surgical treatment, radiation therapy, overall
survival, and cancer specific survival [11].
2.2. Followup and Determination of the Cause of Death. The
cut-off date for determination of death was December 31,
2008. A standard decision algorithm that uses International
Classification of Diseases was used to process causes of death
from death certificates [12]. This study was determined to
be exempted from review by the Institutional Review Board
of the Dana-Farber Cancer Institute/Brigham and Women’s
Hospital.
2.3. Statistical Methods
2.3.1. Comparison of the Distribution of Clinical Character-
istics for the Study Cohort Stratified by Whether a History
of Cancer Existed at the Time of the PC Diagnosis or Not.
We compared the distribution of clinical characteristics of
the 166,104 men amongst those with a cancer diagnosisISRN Oncology 3
Table 2: Unadjusted and adjusted hazard ratios for prostate-cancer-specific mortality for patient and treatment factors.
Patient and treatment factors Number of
men
Number of
events
Univariate analysis
(HR with 95% CI)
Multivariate analysis
(AHR with 95% CI)
Unadjusted HR 𝑃 value Adjusted HR 𝑃 value
Age at diagnosis in years 166104 3809 1.07 (1.066, 1.075) <0.001 1.01 (1.005, 1.012) <0.001
PSA level in ng/mL at diagnosis
(per log unit increase) 166104 3809 3.68 (3.56, 3.81) <0.001 2.02 (1.93, 2.11) <0.001
Gleason score
<6 78385 334 1 (ref.) — 1 (ref.) —
7 62545 834 3.24 (2.86, 3.68) <0.001 2.58 (2.26, 2.94) <0.001
8–10 25174 2641 26.65 (23.78, 29.86) <0.001 9.46 (8.29, 10.79) <0.001
Tumor stage at diagnosis
1c 62405 1341 1 (ref.) — 1 (ref.) —
2a–2c 88064 1584 0.82 (0.76, 0.88) <0.001 0.96 (0.89, 1.04) 0.34
3-4 15635 884 2.66 (2.44, 2.89) <0.001 1.56 (1.42, 1.72) <0.001
Race
African American 20316 624 1.42 (1.30, 1.55) <0.001 1.15 (1.05, 1.26) 0.002
Other 145788 3185 1 (ref.) — 1 (ref.) —
Year of diagnosis in years 166104 3809 0.93 (0.90, 0.96) <0.001 0.92 (0.89, 0.95) <0.001
Management approach
C u r a t i v e 1 2 4 6 2 8 1 1 4 2 1( r e f . ) — 1( r e f . ) —
Other Rx 4076 454 12.5 (11.25, 13.98) <0.001 4.88 (4.27, 5.59) <0.001
Watchful-waiting/active surveillance 37400 2213 6.72 (6.25, 7.22) <0.001 3.23 (2.94, 3.54) <0.001
History of prior cancer at time of PC
diagnosis
N o 1 6 4 6 4 7 3 7 7 9 1( r e f . ) — 1( r e f . ) —
Yes 1457 30 0.86 (0.60, 1.23) 0.41 0.66 (0.45, 0.97) 0.033
HR: hazard ratio. CI: confidence interval. Dx: diagnosis. HR: hazard ratio. PC: prostate cancer. Ref: reference. Rx: treatment.
preceding their PC diagnosis versus those without a prior
cancer .TheW ilcoxonrank-sumtest[13]wasusedtocompare
the distribution of the continuous clinical characteristics and
a Mantel-Haenszel chi square test [14]w a su s e dt oc o m p a r e
the distribution of categorical covariates.
2.3.2. Risk of PCSM and ACM. We used a Fine and Gray [12]
competing risks and Cox regression [15] to assess whether
there was an association between risk of PCSM and ACM,
respectively, in men diagnosed with a prior cancer versus
no prior cancer adjusting for known PC prognostic factors,
curative, noncurative treatment or AS/WW, race, and age at
andyearofdiagnosisofPC.Timezerowasdefinedasthedate
of the PC diagnosis.
Adjusted (𝐴) a n du n a d j u s t e dh a z a r dr a t i o s( H R )w e r e
calculated and are reported along with their 95% confidence
intervals (CI) and associated 𝑃 values. A two-sided 𝑃 value
<0.05 was considered statistically significant. 𝑅 was used for
all calculations related to Fine and Gray and SAS version
9 . 3( S A SI n s t i t u t e ,C a r y ,N o r t hC a r o l i n a )w a su s e df o ra l l
remaining statistical analyses.
2.3.3. Estimates of PCSM and ACM. The cumulative inci-
dence method [16] was used to calculate estimates of PCSM
stratified by whether the patient had a history of cancer
or not at the time of his PC diagnosis. Age adjusted com-
parisons of the estimates were performed using Fine and
Gray’s regression. ACM was defined as one minus overall
survival.EstimatesofACMwerecalculatedusingthemethod
of Kaplan and Meier [17]a n da g ea d j u s t e de s t i m a t e s[ 18]
s t r a t i fi e db yw h e t h e rt h ep a t i e n th a dah i s t o r yo fc a n c e ro r
not at the time of his PC diagnosis were compared using an
age adjusted log rank 𝑃 value.
3. Results
3.1. Comparison of the Distribution of Clinical Characteristics
for the Study Cohort Stratified by Whether a History of Cancer
ExistedattheT imeofthePCDiagnosisorNot. Afteramedian
followup of 2.75 years, 12,453 men died: 3,809 (30.6%) from
PC.PriortothediagnosisofPC,1,457malignanciesoccurred
atamedianof4.8years.AsshowninT able1,menwithaprior
cancer were significantly older at diagnosis (median age: 72
versus 66 years, 𝑃 = 0.001), were followed longer (median
follow up: 3.0 versus 2.75 years, 𝑃 < 0.001), were more likely
to have high-risk PC (30.1% versus 26.8%, 𝑃 = 0.01)b a s e d
on the occurrence of Gleason 8 to 10 PC (19.2% versus 15.1%,
𝑃 < 0.001), and underwent WW or AS more frequently
(30.5% versus 22.5%, 𝑃 < 0.001). In addition, they were4 ISRN Oncology
Table 3: Unadjusted and adjusted hazard ratios for all-cause mortality for patient and treatment factors.
Patient and treatment factors Number of
men
Number of
events
Univariate analysis
(HR with 95% CI)
Multivariate analysis
(AHR with 95% CI)
Unadjusted HR 𝑃 value Adjusted HR 𝑃 value
Age at diagnosis in years 166104 12453 1.09 (1.089, 1.093) <0.001 1.05 (1.046, 1.051) <0.001
PSA level in ng/mL at diagnosis
(per log unit increase) 1 6 6 1 0 4 1 2 4 5 3 2 . 0 9( 2 . 0 6 ,2 . 1 3 ) <0.001 1.38 (1.36, 1.41) <0.001
Gleason score
<67 8 3 8 5 3 5 7 1 1 ( r e f ) — 1 ( r e f ) —
7 62545 4048 1.49 (1.42, 1.56) <0.001 1.35 (1.29, 1.42) <0.001
8–10 25174 4834 4.76 (4.56, 4.97) <0.001 2.46 (2.34, 2.58) <0.001
Tumor stage at diagnosis
1c 62405 5198 1 (ref.) — 1 (ref.) —
2a–2c 88064 5726 0.75 (0.73, 0.78) <0.001 0.98 (0.94, 1.02) 0.28
3-4 15635 1529 1.17 (1.11, 1.24) <0.001 1.30 (1.22, 1.38) <0.001
Race
African American 20316 1950 1.36 (1.30, 1.43) <0.001 1.45 (1.38, 1.52) <0.001
O t h e r 1 4 5 7 8 8 1 0 5 0 3 1( r e f . ) — 1( r e f . ) —
Year of diagnosis in years 166104 12453 0.94 (0.92, 0.96) <0.001 0.96 (0.94, 0.98) <0.001
Management approach
C u r a t i v e 1 2 4 6 2 8 5 0 7 7 1( r e f . ) — 1( r e f . ) —
Other Rx 4076 1023 6.90 (6.45, 7.37) <0.001 3.50 (3.25, 3.75) <0.001
Watchful-waiting/active surveillance 37400 6353 4.62 (4.46, 4.80) <0.001 2.61 (2.50, 2.72) <0.001
History of prior cancer at time of PC
diagnosis
No 164647 12050 1 (ref.) — 1 (ref.) —
Yes 1457 403 4.08 (3.69, 4.50) <0.001 2.92 (2.64, 3.23) <0.001
HR: Hazard ratio. CI: Confidence Interval. Dx: diagnosis. HR: Hazard ratio. PC: prostate cancer. Ref: reference. Rx: treatment.
also less likely to be African American (7.4% versus 12.3%,
𝑃 < 0.001) and they were more likely to have clinical tumor
stage T1c (42.0 versus 37.5%, 𝑃 < 0.001) and were more likely
to be diagnosed earlier in time (𝑃 = 0.035).
3.2. Risk of PCSM and ACM. A ss h o w ni nT a b l e2,f o rm e n
withahistoryofcanceratthetimeofthePCdiagnosisversus
not having the risk of PCSM was significantly decreased
(AHR:0.66(95%CI:(0.45,0.97);𝑃 = 0.033),whereastherisk
ofACMwassignificantlyincreased(AHR:2.92(95%CI:2.64,
3.23); 𝑃 < 0.001)a ss h o w ni nT a b l e3. Given the differences
showninTable1thatshouldhaveledtoanincreaseintherisk
of PCSM amongst men with versus without a prior cancer,
these results suggest competing risks and non curative PC
treatment accounted for the observed reduction in the risk
of PCSM.
3.3.EstimatesofPCSMandACMStratifiedbyPriorHistoryof
Cancer. AsshowninFigure1(a),theage-adjustedcumulative
incidence of PCSM was significantly lower for men with a
prior cancer as compared to those without a history of cancer
prior to the PC diagnosis (𝑃 = 0.012)H o w e v e r ,a g ea d j u s t e d
estimates of all-cause mortality were significantly higher
(𝑃 < 0.001) for men with a prior cancer as compared to no
p r i o rc a n c e r ,a ss h o w ni nF i g u r e1(b).
4. Discussion
Overtreatment remains an issue in the United States for men
with low-risk PC; a target population for whom greater use
of AS may be more appropriate particularly in men with
significant comorbidity [19]. Our results indicate that men
w h oh a dah i s t o r yo fc a n c e rp r i o rt ot h ed i a g n o s i so fP C
were followed longer, were older, and were more likely to
have GS 8 to 10PC and undergo WW or AS compared with
those who did not have a history of cancer. However, despite
the less frequent use of curative treatment in these men who
had more aggressive PC that should have led to an increased
risk of PCSM, these men had a significant decrease in the
riskofPCSMwhiletheirriskofACMincreasedsignificantly,
suggesting that competing risks (prior cancer and other
comorbidities) and not curative PC treatment accounted for
t h er e d u c t i o no fP C S M .Th ec l i n i c a ls i g n i fi c a n c eo ft h e s e
findings is that AS should be more judiciously employed in
men with competing risks. Specifically, while men with low
risk PC are offered AS if their life expectancy is less than 10
y e a r sa sp e rt h e2 0 1 3N C C Ng u i d e l i n e s[ 20]f o rm e nw i t h
unfavorable-risk PC (i.e., intermediate or high-risk) whereISRN Oncology 5
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Figure 1: (a) Age adjusted cumulative incidence estimates of prostate-cancer-specific mortality following prostate cancer diagnosis in men
with or without a history of a prior malignancy 𝑃 = 0.012. (b) Age adjusted estimates of overall survival or all-cause mortality estimates
following prostate cancer diagnosis in men with or without a history of a prior malignancy 𝑃 < 0.001.
ASwouldnotbethepreferredstrategybytheexistingNCCN
guidelines, those who have had a prior cancer diagnosis
should be considered for AS if the expected rate of cure of
the prior CA is low.
Several points require further discussion. First, a recent
study has shown that men with low-risk PC are more likely
to be offered AS when seen in concurrent multidisciplinary
setting rather than sequentially [21]. These results suggest
that when a multidisciplinary team of physicians consult on
a patient AS is more likely to be recommended. Second,
investigators have attempted to define novel assays such as
circulating tumor cell burden [22] and gene profiling [23,
24] that can stratify patients with castration resistant PC
i n t oc o h o r t sw i t hl o n g e ro rs h o r t e rm e d i a ns u r v i v a l s .S u c h
tools are needed in men with low-risk PC in order to more
appropriately select men for AS.
Third, men with a prior history of cancer as shown in
Table 1 were more likely to be diagnosed with Gleason score
8t o1 0p r o s t a t ec a n c e r( 1 9 . 2 %v e r s u s1 5 . 1 % ;𝑃 < 0.001). This
likely reflects the fact that they were also significantly older
at prostate cancer diagnosis (median age: 72 versus 66; 𝑃<
0.001) and advancing age has been shown to be associated
with higher grade prostate cancer [25]. Also these men were
more likely to be diagnosed at an earlier tumor stage (42%
versus 37.5% T1c, 𝑃 < 0.001), which may reflect more active
medical monitoring with PSA screening given the history of
the prior malignancy.
Potential limitations of this study include the inherent
limitations associated with a SEER analysis, including lim-
ited information about the biopsy specimen (number and
extent of positive cores, tertiary Gleason grade 5, perineural
invasion). Also, data on comorbidity other than a prior
history of cancer is lacking. Nevertheless, the results of our
analysis add to the ongoing dialogue about quantifying the
impact competing risks can have on life expectancy when
deciding on whether curative treatment is likely to benefit a
patient with favorable-risk PC. Conversely, some men who
are otherwise healthy with favorable-risk PC may require
immediatecurativetreatmentofPCasopposedtoASinorder
to avoid PCSM. In order to ascertain who these men are
randomized controlled trials evaluating curative treatment
compared to AS should employ a prerandomization strati-
fication by comorbidity using a validated metric of comor-
bidity [9] in order to assess whether treatment compared
to AS benefits all men or only those with no or minimal
comorbidity.
In conclusion, while an attempt is being made to offer
men AS, the degree to which this has been occurring in the
United States between 2004 and 2007 in men with a prior
cancerdoesnotappeartobeadequatetoavoidovertreatment.
Therefore, an assessment of the impact that the prior cancer
has on life expectancy is needed at the time of PC diagnosis
todeterminewhethercurativetreatmentforunfavorable-risk
PC versus AS is appropriate.6 ISRN Oncology
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